Celine Sabatel

The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.

Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth.

Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis.

MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells.